Adding sarcosine to antipsychotic treatment in patients with stable schizophrenia changes the concentrations of neuronal and glial metabolites in the left dorsolateral prefrontal cortex

International Journal of Molecular Sciences

Volumn 16, Issue 10, 2015, Pages 24475-24489

  Strzelecki, Dominik ^a   Podgórski, Michał ^b   Kałużyńska, Olga ^a   Stefańczyk, Ludomir ^b   Kotlicka Antczak, Magdalena ^a   Gmitrowicz, Agnieszka ^a   Grzelak, Piotr ^b  

^a Maria Konopnicka Paediatric Centre   (Poland)

^b Department of Radiology Diagnostic Imaging Medical University of Łódź Barlicki University Hospital No 1 ^*  (Poland)

Author keywords

1H NMR spectroscopy; Dorso lateral prefrontal cortex; Glutamate; NMDA receptor; Sarcosine; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; SARCOSINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; DORSOLATERAL PREFRONTAL CORTEX; FEMALE; GLIA CELL; HUMAN; MALE; NERVE CELL; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SCORING SYSTEM; CONTROLLED STUDY; DRUG EFFECTS; GLIA; METABOLISM; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; NEUROGLIA; NEURONS; PREFRONTAL CORTEX; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SARCOSINE; SCHIZOPHRENIA;

EID: 84945209064     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161024475     Document Type: Article

References (75)

1. McGrath, J.; Saha, S.; Chant, D.; Welham, J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008, 30, 67-76
2. Lewis, D.A.; Lieberman, J.A. Catching up on schizophrenia: Natural history and neurobiology. Neuron 2000, 28, 325-334
3. Wahlberg, KE.; Wynne, LC.; Hakko, H.; Laksy, K.; Moring, J.; Miettunen, J.; Tienari, P. Interaction of genetic risk and adoptive parent communication deviance: Longitudinal prediction of adoptee psychiatric disorders. Psychol. Med. 2004, 34, 1531-1541
4. Potkin, S.G.; Turner, J.A.; Brown, G.G.; McCarthy, G.; Greve, D.N.; Glover, G.H.; Manoach, D.S.; Belger, A.; Diaz, M.; Wible, C.G.; et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr. Bull. 2009, 35, 19-31
5. Morgane, P.J.; Galler, J.R.; Mokler, D.J. A review of systems and networks of the limbic forebrain/limbic midbrain. Prog. Neurobiol. 2005, 75, 143-160
6. Mattson, D.T.; Berk, M.; Lucas, M.D. A neuropsychological study of prefrontal lobe function in the positive and negative subtypes of schizophrenia. J. Genet. Psychol. 1997, 158, 487-494
7. Alvarez, J.A.; Emory, E. Executive function and the frontal lobes: A meta-analytic review. Neuropsychol. Rev. 2006, 16, 17-42
8. Etkin, A.; Gyurak, A.; O’Hara, R. A neurobiological approach to the cognitive deficits of psychiatric disorders. Dialogues Clin. Neurosci. 2013, 15, 419-429
9. Green, M.F.; Kern, R.S.; Heaton, R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr. Res. 2004, 72, 41-51
10. Carlsson, A.; Waters, N.; Waters, S.; Carlsson, M.L. Network interactions in schizophrenia-Therapeutic implications. Brain Res. Rev. 2000, 31, 342-349
11. Coyle, J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 1996, 3, 241-253
12. Olney, J.W.; Newcomer, J.W.; Farber, N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33, 523-533
13. Kantrowitz, J.; Javitt, D.C. Glutamatergic transmission in schizophrenia: From basic research to clinical practice. Curr. Opin. Psychiatry 2012, 25, 96-102
14. Tsai, G.; Lane, H.Y.; Yang, P.; Chong, M.Y.; Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 2004, 55, 452-456
15. Lane, H.Y.; Chang, Y.C.; Liu, Y.C.; Chiu, C.C.; Tsai, G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005, 62, 1196-1204
16. Lane, H.Y.; Lin, C.H.; Huang, Y.J.; Liao, C.H.; Chang, Y.C.; Tsai, G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13, 451-460
17. Amiaz, R.; Kent, I.; Rubinstein, K.; Sela, B.A.; Javitt, D.; Weiser, M. Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia-preliminary study. Isr. J. Psychiatry Relat. Sci. 2015, 52, 12-15
18. Singh, S.P.; Singh, V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25, 859-885
19. Lane, H.Y.; Huang, C.L.; Wu, P.L.; Liu, Y.C.; Chang, Y.C.; Lin, P.Y.; Chen, P.W.; Tsai, G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 2006, 60, 645-649
20. Lane, H.Y.; Liu, Y.C.; Huang, C.L.; Chang, Y.C.; Liau, C.H.; Perng, C.H.; Tsai, G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol. Psychiatry 2008, 63, 9-12
21. Steen, R.G.; Hamer, R.M.; Lieberman, J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis. Neuropsychopharmacology 2005, 30, 1949-1962
22. Brugger, S.; Davis, J.M.; Leucht, S.; Stone, J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-A systematic review and meta-analysis. Biol. Psychiatry 2011, 69, 495-503
23. Kraguljac, N.V.; Reid, M.; White, D.; Jones, R.; den Hollander, J.; Lowman, D.; Lahti, A.C. Neurometabolites in schizophrenia and bipolar disorder-A systematic review and meta-analysis. Psychiatry Res. 2012, 203, 111-125
24. Marsman, A.; van den Heuvel, M.P.; Klomp, D.W.; Kahn, R.S.; Luijten, P.R.; Hulshoff Pol, H.E. Glutamate in schizophrenia: A focused review and meta-analysis of ¹H-MRS studies. Schizophr. Bull. 2013, 39, 120-129
25. Moffett, J.R.; Ross, B.; Arun, P.; Madhavarao, C.N.; Namboodiri, A.M. N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog. Neurobiol. 2007, 81, 89-131
26. Meyerhoff, D.J.; MacKay, S.; Bachman, L.; Poole, N.; Dillon, W.P.; Weiner, M.W.; Fein, G. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: In vivo 1H magnetic resonance spectroscopic imaging. Neurology 1993, 43, 509-515
27. 1H-MRS and un-biased stereology: Can non-invasive measures of N-acetyl-asparate following global ischemia be used as a reliable measure of neuronal damage? Brain Res. 2001, 892, 166-175
28. Bustillo, J.R.; Rowland, L.M.; Jung, R.; Brooks, W.M.; Qualls, C.; Hammond, R.; Hart, B.; Lauriello, J. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008, 33, 2456-2466
29. Mondino, M.; Brunelin, J.; Saoud, M. N-acetyl-aspartate level is decreased in the prefrontal cortex in subjects at-risk for schizophrenia. Front. Psychiatry 2013, 4, 99
30. Fukuzako, H.; Kodama, S.; Fukuzako, T.; Yamada, K.; Doi, W.; Sato, D.; Takigawa, M. Subtype-associated metabolite differences in the temporal lobe in schizophrenia detected by proton magnetic resonance spectroscopy. Psychiatry Res. 1999, 92, 45-56
31. Fukuzako, H. Heritability heightens brain metabolite differences in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2000, 12, 95-97
32. Bartha, R.; Williamson, P.C.; Drost, D.J.; Malla, A.; Carr, T.J.; Cortese, L.; Canaran, G.; Rylett, R.J.; Neufeld, R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton resonance spectroscopy. Arch. Gen. Psychiatry 1997, 54, 959-965
33. Bartha, R.; Al-Semaan, Y.M.; Williamson, P.C.; Drost, D.J.; Malla, A.K.; Carr, T.J.; Densmore, M.; Canaran, G.; Neufeld, R.W. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol. Psychiatry 1999, 45, 1403-1411
34. Bertolino, A.; Callicott, J.H.; Mattay, V.S.; Weidenhammer, K.M.; Rakow, R.; Egan, M.F.; Weinberger, D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 2001, 49, 39-46
35. Bustillo, J.R.; Lauriello, J.; Rowland, L.M.; Thomson, L.M.; Petropoulos, H.; Hammond, R.; Hart, B.; Brooks, W.M. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 2002, 58, 313-321
36. Fannon, D.; Simmons, A.; Tennakoon, L.; O’Céallaigh, S.; Sumich, A.; Doku, V.; Shew, C.; Sharma, T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 2003, 54, 587-598
37. Callicot, J.H.; Bertolino, A.; Egan, M.F.; Egan, M.F.; Mattay, V.S.; Langheim, F.J.; Weinberger, D.R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 2000, 157, 1646-1651
38. Delamillieure, P.; Fernandez, J.; Constans, J.M.; Brazo, P.; Benali, K.; Abadie, P.; Vasse, T.; Thibaut, F.; Courthéoux, P.; Petit, M.; et al. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: Preliminary report. Am. J. Psychiatry 2000, 157, 641-643
39. Tanaka, Y.; Obata, T.; Sassa, T.; Yoshitome, E.; Asai, Y.; Ikehira, H.; Suhara, T.; Okubo, Y.; Nishikawa, T. Quantitative magnetic resonance spectroscopy of schizophrenia: Relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin. Neurosci. 2006, 60, 365-372
40. Yamasue, H.C.; Fukui, T.; Fukuda, R.; Yamada, H.; Yamasaki, S.; Kuroki, N.; Abe, O.; Kasai, K.; Tsujii, K.; Iwanami, A.; et al. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport 2002, 13, 2133-2137
41. Szulc, A.; Galińska, B.; Tarasów, E.; Dzienis, W.; Kubas, B.; Konarzewska, B.; Walecki, J.; Alathiaki, A.S.; Czernikiewicz, A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients: A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 2005, 38, 214-219
42. Braus, D.F.; Ende, G.; Weber-Fahr, W.; Demirakca, T.; Tost, H.; Henn, F.A. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur. Neuropsychopharmacol. 2002, 12, 145-152
43. Braus, D.F.; Ende, G.; Weber-Fahr, W.; Demirakca, T.; Henn, F.A. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: An MRSI study. Pharmacopsychiatry 2001, 34, 251-253
44. 1H-MRS) study. Med. Sci. Monit. 2007, 13, 17-22
45. Moreno, A.; Ross, B.D.; Bluml, S. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by 13C MRS and [1-13C] glucose infusion. J. Neurochem. 2001, 77, 347-350
46. Szulc, A.; Konarzewska, B.; Galińska-Skok, B.; Łazarczyk, J.; Waszkiewicz, N.; Tarasów, E.; Milewski, R.; Walecki, J. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci. Lett. 2013, 547, 37-41
47. Lisman, J.E.; Coyle, J.T.; Green, R.W.; Javitt, D.C.; Benes, F.M.; Heckers, S.; Grace, A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31, 234-242
48. Bitanihirwe, B.K.; Lim, M.P.; Kelley, J.F.; Kaneko, T.; Woo, T.U. Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry 2009, 9, 71
49. Fox, M.D.; Raichle, M.E. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat. Neurosci. Rev. 2007, 8, 700-711
50. Gonzalez-Burgos, G.; Lewis, D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical γ oscillations in schizophrenia. Schizophr. Bull. 2012, 38, 950-957
51. Carlén, M.; Meletis, K.; Siegle, J.H.; Cardin, J.A.; Futai, K.; Vierling-Claassen, D.; Rühlmann, C.; Jones, S.R.; Deisseroth, K.; Sheng, M.; et al. A critical role for NMDA receptors in parvalbumin interneurons for γ rhythm induction and behavior. Mol. Psychiatry 2012, 17, 537-548
52. Kocsis, B. Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical γ oscillations. Biol. Psychiatry 2012, 71, 987-995
53. Fornito, A.; Harrison, B.J.; Zalesky, A.; Simons, J.S. Competitive and cooperative dynamics of large-scale brain functional networks supporting recollection. Proc. Natl. Acad. Sci. USA 2012, 109, 12788-12793
54. Garrity, A.G.; Pearlson, G.D.; McKiernan, K.; Lloyd, D.; Kiehl, K.A.; Calhoun, V.D. Aberrant “default mode” functional connectivity in schizophrenia. Am. J. Psychiatry 2007, 164, 450-457
55. Landin-Romero, R.; McKenna, P.J.; Salgado-Pineda, P.; Sarró, S.; Aguirre, C.; Sarri, C.; Compte, A.; Bosque, C.; Blanch, J.; Salvador, R.; et al. Failure of deactivation in the default mode network: A trait marker for schizophrenia? Psychol. Med. 2015, 45, 1315-1325
56. Cohen, S.M.; Tsien, R.W.; Goff, D.C.; Halassa, M.M. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr. Res. 2015, doi:10.1016/j.schres.2014.12.026
57. Meda, S.A.; Ruaño, G.; Windemuth, A.; O’Neil, K.; Berwise, C.; Dunn, S.M.; Boccaccio, L.E.; Narayanan, B.; Kocherla, M.; Sprooten, E.; et al. Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. Proc. Natl. Acad. Sci. USA 2014, 111, E2066-E2075
58. Dodell-Feder, D.; Delisi, L.E.; Hooker, C.I. The relationship between default mode network connectivity and social functioning in individuals at familial high-risk for schizophrenia. Schizophr. Res. 2014, 156, 87-95
59. Poels, E.M.P.; Kegeles, L.S.; Kantrowitz, J.T.; Javitt, D.C.; Lieberman, J.A.; Abi-Dargham, A.; Girgis, R.R. Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophr. Res. 2014, 152, 325-332
60. Kegeles, L.S.; Mao, X.; Stanford, A.D.; Girgis, R.; Ojeil, N.; Xu, X.; Gil, R.; Slifstein, M.; Abi-Dargham, A.; Lisanby, S.H.; et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69, 449-459
61. Stanley, J.A.; Williamson, P.C.; Drost, D.J.; Rylett, R.J.; Carr, T.J.; Malla, A.; Thompson, R.T. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr. Bull. 1996, 22, 597-609
62. Goto, N.; Yoshimura, R.; Kakeda, S.; Nishimura, J.; Moriya, J.; Hayashi, K.; Katsuki, A.; Hori, H.; Umene-Nakano, W.; Ikenouchi-Sugita, A.; et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr. Dis. Treat. 2012, 8, 119-122
63. Szulc, A.; Galińska, B.; Tarasów, E.; Waszkiewicz, N.; Konarzewska, B.; Poplawska, R.; Bibułowicz, D.; Simonienko, K.; Walecki, J. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry 2011, 44, 148-157
64. 1H-MRS: Relationship to ketamine-induced psychopathology. Mol. Psychiatry 2012, 17, 664-665
65. Rowland, L.M.; Bustillo, J.R.; Mullins, P.G.; Jung, R.E.; Lenroot, R.; Landgraf, E.; Barrow, R.; Yeo, R.; Lauriello, J.; Brooks, W.M. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am. J. Psychiatry 2005, 162, 394-396
66. Ohrmann, P.; Siegmund, A.; Suslow, T.; Spitzberg, K.; Kersting, A.; Arolt, V.; Heindel, W.; Pfleiderer, B. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: A proton magnetic resonance spectroscopy study. Schizophr. Res. 2005, 73, 153-157
67. Yoo, S.Y.; Yeon, S.; Choi, C.H.; Kang, D.H.; Lee, J.M.; Shin, N.Y.; Jung, W.H.; Choi, J.S.; Jang, D.P.; Kwon, J.S. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr. Res. 2009, 111, 86-93
68. Szulc, A.; Galińska-Skok, B.; Tarasów, E.; Konarzewska, B.; Waszkiewicz, N.; Hykiel, R.; Walecki, J. Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia. Med. Sci. Monit. 2012, 18, CR390-CR398
69. Bustillo, J.R. Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: A critical update. Dialogues Clin. Neurosci. 2013, 15, 329-337
70. 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr. Res. 2008, 102, 163-170
71. Moraga-Amaro, R.; Jerez-Baraona, J.M.; Simon, F.; Stehberg, J. Role of astrocytes in memory and psychiatric disorders. J. Physiol. Paris 2014, 108, 240-251
72. 1H-MRS study. NeuroImage Clin. 2014, 6, 398-407
73. Schwerk, A.; Alves, F.D.; Pouwels, P.J.; van Amelsvoort, T. Metabolic alterations associated with schizophrenia: A critical evaluation of proton magnetic resonance spectroscopy studies. J. Neurochem. 2014, 128, 1-87
74. Singh, S.P.; Singh, V.; Kar, N.; Chan, K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br. J. Psychiatry 2010, 197, 174-179
75. Kay, S.R.; Fiszbein, A.; Opfer, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13, 261-276